Cerebral Vascular Stent Market Analysis

Global Cerebral Vascular Stent Market Overview

Cerebral Vascular Stent Market Size was valued at USD 0.41 Billion in 2023. The Global Cerebral Vascular Stent industry is projected to grow from USD 0.45 Billion in 2024 to USD 0.86 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 8.46% during the forecast period (2024 - 2032).

Cerebral vascular stents are small mesh-like tubes that are not coated or covered in any way. Stents are put into the brain arteries to treat brain aneurysms, intracranial stenosis, and keep blood flowing through narrowed blood vessels. Brain stents are also used to remove blood clots that have formed in the brain.The major factors driving the cerebral vascular stent market include the rising prevalence of cerebral vascular diseasesand the growing geriatric population. However, post-surgery complications may hamper the cerebral vascular stent market growth.

The government regulatory bodies keep a close watch on the approved product performance, ensuring that the products are working as expected and no adverse effects are found. The product approvals take place after careful considerations about the risks and benefits involved with the product. When a technology designed for a specific patient population is utilized in other ways, the benefit-risk paradigm can shift negatively. For instance, the Wingspan Stent System by Stryker (US), for example, is only approved for use in a small group of individuals with a life-threatening neurological disease was found to be more lethal with higher stroke risks when used in patients outside the FDA approved indication. In another instance, in March 2020, FDA recalled all Medtronic’s Pipeline Flex stent system products citing the products have the potential to fracture during the implantation procedure. Hence, the regulatory bodies play a significant role in approvals andafter-sales monitoring. 

COVID-19 Analysis:

COVID-19 has severely impacted the world with disruptions in the supply chain, research & development, and cerebral vascular stent  market growth. According to our database, in May 2021, it is estimated that the global GDP was at a loss of 4.5%, amounting to about USD 3.94 trillion is lost in economic output. The effects were also felt in the global cerebral vascular stent market. During the COVID-19 pandemic, many players in the global cerebral vascular stents market saw a sharp drop in sales. Furthermore, most players have ceased their production activities. As a result, vendors in the global cerebral vascular stent market are increasing their focus on strategizing business moves in response to the recent COVID-19 pandemic.

Many companies in the cerebral vascular stents sector start production with skeleton employees and adhere to all government restrictions. However, the worldwide cerebral vascular stents market is predicted to resume normal operations in a short amount of time, with promising growth in the years ahead. The subsequent relaxations in the government regulations in several countries supplement the fact. 

The increased incidence of cerebrovascular illnesses and the aging of the global population are the primary forces propelling the market for cerebral vascular stents. Although cerebrovascular disorders can affect persons of any age, from infants to the elderly, the chance of developing one rises in tandem with chronological age. Changes in the morphology and function of the brain's blood vessels are a direct result of aging, rendering the brain more susceptible to cerebrovascular illnesses. However, potential difficulties after surgery may slow the expansion of the market for cerebral vascular stents. 

Government regulatory authorities monitor the effectiveness of licensed items to make sure they are doing their jobs and have no unintended consequences. Risks and advantages are weighed thoroughly before a product is given the green light. The benefit-risk paradigm can shift unfavorably when a device developed for one patient population is used for another.

The innovative cerebral vascular stent market will also benefit from the growing healthcare sector and expanding research capacities. The global market for cerebral vascular stents will also benefit from government funding for stroke care. Stents placed in the cerebral vasculature are often manufactured by large multinational corporations. Market dominators have gotten to where they are today by spending more money on research and developing a more efficient distribution network. In addition, as people become more informed, new, smaller players are appearing in markets around the world.

Many manufacturers of cerebral vascular stents start manufacturing with a small number of staff, taking care to follow all regulations. However, it is expected that the global market for cerebral vascular stents will return to normal operations in a short period of time, with promising growth in the years to come. The reality is bolstered by later easings of government laws in various nations. 

June 2023: Patients with complex peripheral arterial disease (PAD) can now be treated with the DETOUR System, a medical device developed by Endologix LLC, a privately held, global medical device company committed to providing disruptive therapies for the interventional treatment of vascular disease. Endologix's PTAB therapy is a continuation of the company's tradition of innovative, life-changing vascular treatments. Patients with the greatest unmet clinical requirements are the company's first priority, and the DETOUR System marks a major advancement in the treatment of PAD. 

Cerebral Vascular Stent Market Trends

Drivers

• Rising prevalence of cerebral vascular diseases

According to the American Association of Neurological Surgeons (AANS), stroke, carotid stenosis, vertebral stenosis &intracranial stenosis, aneurysms, and vascular malformations are some cerebrovascular diseases caused by the restricted blood flow to the brain. Blood artery constriction (stenosis), clot development (thrombosis), blockage (embolism), and blood vessel rupture can all cause blood flow restrictions (hemorrhage). Ischemia (lack of blood supply to the brain) damages brain tissue and can lead to a stroke.

According to the World Stroke Organization (WSO)’s Global Stroke Fact Sheet 2019, 13 million new cases of stroke are diagnosed globally every year, and over 80 million people have experienced stroke currently living.  According to the report, one in four people will experience a stroke in their lifetime. Cerebral vascular stents are placed appropriately to improve blood flow in the brain and treat or prevent strokes from happening. Therefore, the high prevalence of cerebral disorders is likely to drive the cerebral vascular stent market significantly.

• Rising geriatric population

Even though cerebrovascular disorders can occur at any age, from infants to old age people, the risk of getting such a disorder increases with age. Aging causes vascular morphological and functional changes in the brain, making it more vulnerable to cerebrovascular disorders.According to a report published by Mayo Clinic, the US, in May 2019, the most powerful non-modifiable risk factor for incident stroke is aging, and the risk doubles every ten years after the age of 55. Around three-quarters of all strokes occur in those over the age of 65. The frequency of incident strokes in older persons is likely to increase with the growing population crossing 65 years of age.

According to a report published by United Nations (UN) in December 2020, the older population is growing rapidly due to factors such as increasing levels of life expectancy and decreasing fertility levels; about 727 million peopleaged 65 years or over were living in 2020, and this number is projected to increase to 1.5 billion approximately in 2050. Globally, the population aged 65 years or over is expected to increase from 9.3 per cent in 2020 to around 16.0 per cent in 2050.Hence, the increasing geriatric population will supplement the growth of the cerebral vascular stent market.

Opportunities

• Increasing clinical trials and approvals for cerebral vascular stents

The increase in the number of clinical trials for cerebral vascular stents is expected to significantly boost cerebral vascular stent market growth when the regulatory bodies approve the products. Several products are also getting expanded indication approvals. For instance, Stryker’s (US) Neuroform Atlas received expanded indication from the FDAfor use in the posterior circulation applications in the brain.

Several recent product approvals further supplement the cerebral vascular stent market growth. For instance, the Pipeline Flex Embolization Device, by Micro Therapeutics, Inc. (US), a product for treating brain aneurysms, was approved by the FDA in December 2018. FDA approved another product called Neuroform Atlas Stent System by Stryker (US) in May 2019. Furthermore, In December 2019, FRED System, a stent product by MicroVention, Inc. (US), was also approved by FDA for brain aneurysm treatment.

• Post-surgery complications for cerebral vascular stents

Some of the common issues that can occur during the procedure include an arterial puncture, stent movement, injury to the arterial lining resulting in an arterial dissection, bleeding into the brain, and stroke due to artery obstruction.According to National Heart Lung and Blood Institute, one to two percent of people who undergo stent surgery develop a blood clot at the stent site. However, the benefits of using stents outweigh the risks associated.

Value Chain Analysis

The cerebral vascular stent market is growing steadily due to the rising number of players coming forward with new and better products. The value chain analysis of the cerebral vascular stent market comprises five major components starting with the research & development and designing, followed by manufacturing the products, distribution & sales, and post-sales services. 

Research and development start with conceptualizing, followed by design, then development, and lastly, testing. The R&D segment comprises 25-30% of the value chain. After the product designs are final, the manufacturing of the product starts. Manufacturing consists of 45-50% of the value chain.The manufacturing components are sometimes outsourced. Outsourcing eliminates manufacturing process activities of some parts and helps to quicker the process. Then comes distribution and sales, which is essential for any industry. Here, awareness about the products is spread across the market to attain interested customers for the product. It consists of 10-15% of the value chain. And lastly comes post-sales services. The post-marketing monitoring stage begins with a periodic safety update report of the product, which is to be submitted to the FDA after the device comes into the market and accounts for around 5% of the value chain. In this step, sometimes product recalls also occur if some long-term issues related to the products are discovered. For instance, in March 2020, FDA recalled Pipeline Flex brain stent products of Medtronic plc (Ireland),citing fracture reports during the implantation procedure.

Cerebral Vascular Stent Market Segment Insights

 Cerebral Vascular Stent Type Insights

• Tantalum

Tantalum is a rare metal with an atomic coefficient of 73, a density of 16.65 grams per cubic meter, and a melting point of 2,996 degrees Celsius.Tantalum possesses specific characteristics that make it a viable material for cerebral vascular stents:

• Its high density helps in radiation resistance and in location and release of the stent


• Its nonmagnetic properties make it highly compatible with Nuclear Magnetic Resonance(NMR) which facilitates further follow-ups


• Excellent non-corrosive and biocompatible properties


• A negatively charged oxide layer on its surface that prevents blood platelets from interacting with and adhering to it

However, the stents woven from tantalum wire have a low radial supporting strength, limiting their use in clinical practice.

• Stainless steel

The most common use of stainless steel is in the preparation of balloon dilatation intravascular stents. A common example is 316L stainless steel. Properties such as good mechanical performance, traceable characteristics, and low cost and have wide applications. However, it also has several limitations such as poor corrosion protection, low biocompatibility, and risks of toxicity from Cr and Ni., which hamper its clinical applications.

• Nitinol

Nitinols are alloys of nickel and titanium, which show properties that are perfect for self-expanding stents. The self-expanding properties of nitinol help make it possible to place nitinol stents in position without the use of expanding balloons. Nitinol stents are made slightly larger than the target vessel size and placed in a delivery system. They arrange themselves against the vessel’s wall after deployment with high resistance to outside forces.

Some examples of nitinol cerebral vascular stents are Neuroform and Wingspan stent by Stryker (US) and Codman Enterprise Vascular Reconstruction Device by Johnson and Johnson (US).

Cerebral Vascular Stent End User Insights

• Hospitals

As the number of cerebrovascular disorders increases, the demand for cerebral vascular stents in hospitals is also positively impacted. Hospitals held a majority share in 2020due to the high cerebral vascular stenting procedures carried out in a hospital due to rising stroke cases and other cerebrovascular disorders.

According to the World Stroke Organization (WSO)’s Global Stroke Fact Sheet 2019, 13 million new cases of stroke are diagnosed globally every year, i.e., 13 million new people who need medical assistance in hospitals, which is apart from the patients already getting care in hospitals.

• Ambulatory Surgical Centers

Ambulatory surgery centers are medical care facilities that provide outpatient services. Outpatient services can include an array of services, including carrying out surgeries, minimally invasive therapies, and other procedures. Moreover, ambulatory surgery centers enhance the safety of care transitions and establish patient safety and strategies for clinicians and other medical professionals to improve performance and maintain workflow, thus driving the growth of this segment.

The surging incidence rates of cerebral vascular disorders push for faster treatment access and alternatives. The reduced turnaround time that ambulatory surgical centers provide to the patients and the other factors stated above are driving the growth of this segment.

February 2023:The team at Synchron, a brain interface firm, is developing cutting-edge tools to improve the quality of life for paralyzed individuals. People with no or extremely limited physical mobility can use technology like cursors and smart home gadgets with their minds thanks to the Synchron Switch, which is implanted through the blood vessels. Three individuals in the United States and four in Australia have been treated with the experimental therapy thus far. Synchron's BCIs are implanted using a less invasive method that expands upon decades of research in endovascular procedures, while many of its competitors require open-brain surgery.

Cerebral Vascular Stent Regional Insights

• North America

Risingcerebrovascular disorder cases and increasing R&D expenditure are likely to drive cerebral vascular stent market growth during the forecast period for this region.According to the Brain Aneurysm Foundation data for 2019, an estimated 6.5 million persons in the United States have an unruptured brain aneurysm, or around one in every 50 people. Each year, about 30,000 people in the United States have a brain aneurysm rupture. Furthermore, with an uneven 3:2 ratio, women are more prone than men to get a brain aneurysm.

Key players in the regionfocus on mergers and acquisitions, contractual agreements, new product launches, increasing investments, and partnering with other players to expand their global footprint. For instance, in May 2019, Stryker (US) announced the FDA approval of its brain aneurysm stent system called Neuroform Atlas. In August 2018, Boston Scientific (US) announced an agreement to acquire VENITI, Inc. (US), specializing in venous stent systems products. 

• Europe

The rising prevalence of cerebrovascular diseases in Europe, the presence of advanced medical facilities, and rising healthcare expenditure are driving the cerebral vascular stent market in the region.For instance, according to Stroke Alliance for Europe, there are 88,922 incidences of stroke in the country every year, and is expected to increase by 30% from 2015 to 2035. This is further supplemented by the increasing geriatric population in the region. For instance, according to the AGE UK Organization’s report of 2019, there are nearly 12 million (11,989,322) people aged 65 and above in the UK, out of which more than 5 million people are over 75 years of age. By 2032, they estimated that one in five people wouldbe aged more than 65 years of age.

The large part of the worldwide cerebral vascular stent market owned by Europe is due to revenue contributions from developed countries in Western Europe, such as the United Kingdom, Germany, France, and Italy. During the projected period, the cerebral vascular stents market in Europe is expected to be driven by the increasing base of the target patient population, namely elderly persons (over the age of 65), and increasing cerebral vascular disorders in the region.

• Asia-Pacific

Asia-Pacific is projected to be the fastest-growing regional market during the forecast period due to factors such as a large customer base, high prevalence of cerebrovascular disorders, and improving healthcare infrastructure. According to the Chinese Stroke Associationin their report China Stroke Statistics 2019, China accounts for the highest number of stroke cases in the world with 149.49 per 100,000, accounting for 1.57 million deaths in 2018.

Furthermore, the improving healthcare infrastructure and advancing research capabilities will help develop a novel cerebral vascular stent market. Moreover, government support regarding stroke care shall supplement the cerebral vascular stent  market growth in the region.

• Rest of the World

The rest of the world comprises Middle East, Africa, and Latin America. Due to the high rate of acceptance of modern medical devices and the rapid expansion of the health care industry in these regions, the cerebral vascular stent marketis projected to be a lucrative market in the near future. However, the low incidence and prevalence of cerebral vascular disorders in the region might hamper growth in the forecast period.

Competitive Landscape

Stryker (US) is one of the major key players in the cerebral vascular stent market. The company offers several stenting products, including Neuroform EZ, Surpass Evolve, Surpass Streamline, Wingspan Stent System, and its latest offering, Neuroform Atlas, which received FDA approval In May 2019. The Neuroform Atlas received the FDA approval for use in a new indication for posterior circulation in August 2020. 

The majority ofcerebral vascular stents are produced by major global companies. Industry leaders have built their position in the market by investing more in research and having a better distribution system. Furthermore, due to increased awareness, some small players are emerging throughout Asia-Pacific. This has also aided the market’s expansion.In addition, the market players are offering mergers and acquisitions, contractual agreements, new product launches, increasing investments, and partnering with other players to expand their global footprint.

List of Key Companies Covered in this Report:

• Stryker Corporation (US)


• Boston Scientific Corporation (US)


• Johnson & Johnson Services, Inc. (US)


• Terumo Corporation (Japan)


• Cook Medical (US)


• Penumbra, Inc. (US)


• Medtronic plc (Ireland)


• Acandis GmbH (Germany)


• Phenox GmbH (Germany)


• MicroPort Scientific Corporation (China)

Recent Developments

• In August 2020, Stryker (US) announced that its brain aneurysm stent called Neuroform Atlas receivedFDA approval for posterior circulation use for treating brain aneurysm


• In August 2020, Synchron (US) announced that that the company received Breakthrough Device designation for Stentrode from the FDA, which is a stent with brain-computer interphase capabilities


• In March 2020, FDA recalled all Medtronic(Ireland) brain stent products called Pipeline Flex stent citing the products have the potential to fracture during the implantation procedure


• In December 2019, MicroVention, Inc. (US) received FDA approval for FRED System, a stent system for treatingbrain aneurysm.


• In May 2019, Stryker(US) announced the FDA approval of its brain aneurysm stent system called Neuroform Atlas


• In December 2019, MicroVention, Inc.’s (US) FRED® System, a stent system for treating brain aneurysm got approved by FDA

The study covers the existing short-term and long-term market effect, as well as helping decision-makers to draught short-term and long-term plans for businesses by region. The report covers North America, Europe, Asia-Pacific, and the rest of the world. The report analyzes market drivers, restraints, opportunities, challenges, Porter’s Five Forces, Value Chain, and impact of COVID-19 on the market.

Cerebral Vascular Stent Market Segmentation

 Cerebral Vascular Stent Type Outlook

• Tantalum


• Stainless steel


• Nitinol

Cerebral Vascular Stent End User Outlook

• Hospitals& Clinics


• Ambulatory Surgery Centers

Cerebral Vascular Stent Region Outlook

• North America
  
  
  
  • US
  
  
  • Canada
  
  
  
  


• Europe
  
  
  
  • Germany
  
  
  • France
  
  
  • UK
  
  
  • Italy
  
  
  • Spain
  
  
  • Rest of Europe
  
  
  
  


• Asia-Pacific
  
  
  
  • China
  
  
  • Japan
  
  
  • India
  
  
  • Australia
  
  
  • South Korea
  
  
  • Rest of Asia-Pacific
  
  
  
  


• Rest of the World
  
  
  
  • Middle East
  
  
  • Africa
  
  
  • Latin America